Botanix News Hub
Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Botanix Releases Quarterly Reports
/ in NewsThe Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q2 FY2026 have been released.
Quarterly Update Webinar 27 January | Registration Open
/ in NewsJoin our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on Tuesday, 27 January at 10.30 am AEDT / 7.30 am AWST for an important update.
Botanix announces regulatory approval of ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea
/ in NewsBotanix announced that Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea.
Botanix featured at global investor conference
/ in NewsBotanix Executive Chairman Vince Ippolito will be a featured presenter on Tuesday, 9 September at the HC Wainwright 27th Annual Global Investment Conference in New York, NY (US).
Sofdra posters presented at dermatology conferences
/ in NewsThree Sofdra scientific posters were accepted and exhibited at leading dermatology
AGM Chairman’s Address is now available
/ in NewsBotanix expresses thanks to valued shareholders and other significant
Botanix Supports Hyperhidrosis Awareness Month
/ in NewsWe share the International Hyperhidrosis Society’s belief that ‘together
Botanix Presents at Canaccord Conference
/ in NewsBotanix Presents at Canaccord Conference
Botanix Releases Quarterly Reports
/ in NewsBotanix Releases Quarterly Reports
Quarterly Update Webinar October 20 | Registration Open
/ in NewsQuarterly Update Webinar October 20 | Registration Open
Botanix announces regulatory approval of ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea
/ in NewsBotanix announced that Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel
Botanix Releases Annual Report
/ in NewsThe Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million cash and $15.3 million in undrawn debt.
Dr Patricia Walker Joins Botanix Board
/ in NewsDr Patricia Walker Joins Botanix Board
Botanix investor presentation at Canaccord Genuity event
/ in NewsBotanix Chief Executive Officer Dr Howie McKibbon will be a featured presenter at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA
Sofpironium topical gel (Sofdra) featured in JAAD
/ in NewsBotanix is pleased to share that an article featuring sofpironium topical gel, 12.45% (Sofdra) appears in the July 2025
Dr Boreham’s Crucible features Botanix
/ in NewsBotanix Pharmaceuticals has been featured in Dr Boreham’s Crucible, a column focusing on the Australian biotechnology and healthcare sectors.
Botanix signs debt facility with Kreos Capital
/ in NewsBotanix has entered into documentation with Kreos Capital for a loan facility of up to US$30 million (~A$48 million).
Euroz Hartleys Research Report | BOT: All Bark No Bite
/ in NewsEuroz Hartleys has published a research note on Botanix maintaining a price target of $0.80.
Botanix included in ASX 300 Index
/ in NewsBotanix Pharmaceuticals is very pleased to announce that the Company will be included in the S&P/ASX 300 Index
Stockhead | Interview with Howie McKibbon
/ in NewsBotanix CEO Howie McKibbon spoke with Stockhead’s Tylah Tully about Botanix’s elevation to the S&P/ASX 300 index, and the Company’s ambitions to become a global leader in dermatology innovation.
Euroz Hartleys Research Report
/ in NewsEuroz Hartleys has published a research note on Botanix forecasting strong sales momentum for Sofdra™.
The West Australian: ‘Botanix ships first batch of sweat-stopper gel’
/ in NewsBotanix’s significant progress towards commercialisation has been spotlighted in The West Australian’s Business section
First Sofdra™ prescriptions as commercialization ramps up
/ in NewsFirst prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025.
Botanix adds Payer coverage representing ~65 million commercial lives
/ in NewsAscent Health, second largest Payer (insurer) organisation in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%.
From The Helm | Interview with CEO Dr Howie McKibbon
/ in NewsWhile in Australia last month, Botanix CEO Dr Howie McKibbon spoke with Bell Direct’s Grady Wulff about the Company’s FDA-approved product, Sofdra™
Ausbiz | Interview with Howie McKibbon
/ in NewsBotanix CEO Howie McKibbon recently visited Australia to meet with investors, and to present at the ASX Small and Mid-Cap Conference and the E&P Small Cap Healthcare Conference.
Botanix staffing update and AGM Notice of Meeting
/ in NewsBotanix provides a staffing update as it prepares for the planned launch of Sofdra™ (sofpironium) 12.45% in Q4 CY2024
Botanix presentation at leading investor conferences and roadshow
/ in NewsBotanix CEO Howie McKibbon will be a featured presenter at ASX Small and Mid-Cap Conference on Wednesday, 25 September
Appendix 4E Released and Commercial Day Webinar Announced
/ in NewsMark your calendar for the Company’s Commercial Day Webinar on Tuesday 17 September
Botanix Releases Quarterly Reports
/ in NewsQuarterly Activity Report and 4C Quarterly Cash Flow Report released.
Euroz Hartleys Upgrades BOT to Buy
/ in NewsEuroz Hartleys’ Seth Lizee asserts that “the market opportunity for Sofdra is significant.
Botanix secures commitments for $70 million
/ in NewsBotanix has received firm commitments for $70 million capital raising via an institutional placement.
Final Sofdra™ Labelling Discussions with FDA
/ in NewsBotanix has submitted the last label materials to the US Food & Drug Administration (FDA) for Sofdra™ a pending prescription treatment for excessive underarm sweating.
Botanix Included in the All Ordinaries Index
/ in NewsBotanix Pharmaceuticals (ASX:BOT) is honoured to announce the Company’s inclusion in the ASX All Ordinaries Index.
Botanix appoints Graeme Morissey CFO
/ in NewsBotanix Pharmaceuticals (ASX:BOT) is pleased to announce the appointment of Graeme Morissey as Chief Financial Officer (“CFO”) of the Company
Botanix to Present at Euroz Hartleys Institutional Conference
/ in NewsBotanix Pharmaceuticals (ASX:BOT) announced that Botanix CEO Dr Howie McKibbon will be among the featured presenters tomorrow at the annual Euroz Hartleys
Euroz Hartleys Healthcare Forum Presentation
/ in NewsBotanix Pharmaceuticals (ASX:BOT) announced that Botanix CEO, Dr Howie McKibbon, is presenting at the Euroz Hartleys Healthcare Forum being held today in Perth, Western Australia..
Botanix resubmission of NDA for Sofdra™ accepted
/ in NewsBotanix resubmission of NDA for Sofdra™ completed
/ in NewsBotanix Pharmaceuticals has announced that the Company has successfully completed resubmission of the new drug application (NDA) for Sofdra™.
Successful completion of human factors validation study assessing revised Instructions for Use for Sofdra™
/ in NewsBotanix Pharmaceuticals has announced that the Company has successfully completed the planned human factors validation study assessing revised Instructions for Use (IFU) for Sofdra™.
FDA confirms approach to Sofdra™ NDA resubmission
/ in NewsBotanix Pharmaceuticals has announced that the Company has received feedback from FDA following its “end of review” Type A meeting request in respect to the Sofdra™ new drug application review that was completed in September 2023.
$13.5M institutional placement
/ in NewsBotanix has today announced it has received firm commitments for $13.5m via an institutional placement, with proceeds to support preparation for commercial launch activities for Sofdra™.
Research note | Continued Strong Sales from Japanese Partner
/ in NewsEuroz Hartleys has published a research note on the performance of Kaken Pharmaceuticals, our Japanese pharmaceutical partner, which may provide insight into rapid growth potential for Sofpironium Bromide in the US.
Botanix Pharmaceuticals signs exclusive agreement with leading telehealth provider UpScriptHealth®
/ in NewsBotanix Pharmaceuticals (ASX:BOT) has signed an exclusive agreement with UpScriptHealth® to provide the digital platform
FDA conditionally approves Sofdra™ as a trade name for sofpironium bromide
/ in NewsBotanix (ASX: BOT) announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved a trade name for sofpironium bromide gel, 15%.
Dr Howie McKibbon appointed Chief Executive Officer
/ in NewsBotanix has announced the promotion of Dr Howie McKibbon to the role of Chief Executive Officer, from his current position as Chief Operating Officer.
A$12.5 million institutional placement
/ in NewsBotanix has announced it has secured firm commitments for A$12.5 million via an institutional placement.
New territory licensed for Sofpironium Bromide with partner Kaken
/ in NewsBotanix has today announced that our partner Kaken Pharmaceutical Co Ltd, has secured a new sublicense and distribution agreement for Sofpironium Bromide in Korea.
Botanix secures commitments for A $10 million via institutional placement
/ in NewsBotanix lifted a trading halt this morning, sharing news that it has secured commitments of A$10.0million via institutional investors to accelerate the marketing and launch activities for Sofpironium Bromide.
Mid-Cycle Review Complete + Capital Raise
/ in NewsBotanix has today released an update regarding the progress of its lead product, Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis – a medical condition where excessive sweating occurs beyond what is needed to maintain normal body temperature.
Special Report | Stockhead
/ in NewsBotanix has today appeared in Stockhead in an article titled, ‘As it awaits crucial FDA approval Botanix reckons Aussies have a penchant for backing high-risk companies.’
This broker says Botanix Pharma’s share price could more than triple on an FDA approval | Stockhead
/ in NewsA recent analyst report by Euroz Hartleys predicting significant upside for Botanix if the Company’s Sofpironium Bromide New Drug Application (NDA) is successful, has been featured on Stockhead.
BOT Video | Not To Be Missed
/ in NewsBotanix has united three experts to explain why its lead product, Sofpironium Bromide
Quarterly Activities Report and 4C Quarterly Cash Flow Report
/ in NewsBotanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 December 2022.
JP Morgan Healthcare Conference Presentation
/ in NewsBotanix will be attending the JP Morgan Healthcare Conference in San Francisco this week.
FDA confirmation Sofpironium Bromide NDA is formally under review
/ in NewsBotanix has today announced that it has received formal written communication from the FDA, confirming that the New Drug Application (NDA) for Sofpironium Bromide is suitable for substantive review, and that no issues have been identified.
SPP Now Open
/ in NewsBotanix’s recently announced Share Purchase Plan (SPP) to raise up to A$3 million is now open for eligible AU/NZ shareholders.
A$5 million strategic Placement + Share Purchase Plan
/ in NewsBotanix (ASX:BOT) has today lifted its trading halt, sharing news that it has secured a commitment of
Promotion of Dr Howie McKibbon to Chief Operating Officer
/ in NewsBotanix has announced the promotion of Dr Howie McKibbon to the role of Chief Operating Officer, from his current position as Chief Commercial Officer.
Video Interview | Howie McKibbon
/ in NewsBotanix’s Chief Commercial Officer, Howie McKibbon, was interviewed on Ausbiz this week to discuss the positive results from our BTX 1702 Phase 1b/2 clinical trial for rosacea.
Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea
/ in NewsBotanix has released positive data from its BTX1702 rosacea clinical study.
Botanix submits NDA for FDA approval of Sofpironium Bromide
/ in NewsBotanix has today announced the submission of a New Drug Application to the FDA for approval of Sofpironium Bromide
Capital Raise Update
/ in NewsBotanix has announced it has now closed the first tranche of its anticipated $7.5 million placement to new and existing institutional and sophisticated investors.
$7.5m Capital Raise
/ in NewsBotanix has today announced it has received strong commitments to raise $7.5m through a placement to Australian and international institutions and sophisticated investors.
NDA filing accelerated and trials fully enrolled
/ in NewsBotanix has today announced the New Drug Approval (NDA) submission to the FDA for our recently acquired dermatology asset, Sofpironium Bromide for the treatment of excessive underarm sweating, will now be ready to file in Q3 2022.
Herald Sun + Daily Telegraph | Sofpironium Bromide Story
/ in NewsHerald Sun Reporter, Owen Leonard, met with Botanix executives while they were in Australia this week and has published a story about the Company’s recent acquisition of Sofpironium Bromide.
Euroz Hartleys Report | ‘Transformational Acquisition’
/ in NewsBotanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the Company’s recent acquisition of Sofpironium Bromide.
Significant R&D Tax Incentive Refund
/ in NewsBotanix has today announced it has received a Research and Development (R&D) Tax Incentive Refund of A$3,669,439 for the 2021/2022 financial year.